The research abstract "LEADS BIOLABS-B(09887)" has been selected for presentation at the 2026 AACR Annual Meeting.

LEADS BIOLABS-B(09887) has announced that two preclinical pipeline research outcomes will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The meeting will take place at the San Diego Convention Center in San Diego, California, from April 17 to 22, 2026. The two studies demonstrate the company's innovative research on T cell engager drug conjugates (TDC) and dual-targeted ADC, further validating the company's synergistic research and development strategy of the three core proprietary technology platforms, LeadsBodyTM (CD3 T-Cell Engager platform), X-bodyTM (4-1BB Engager platform), and TOPiKineticsTM (ADC technology platform). LBL-054 TDC is a globally pioneering targeted CDH17 bispecific ADC developed based on the company's proprietary antibody platform and carrying the company's proprietary TOPiKineticsTM linker payload. By combining TCE and ADC dual mechanisms, it achieves precise treatment with high efficacy and low toxicity for gastrointestinal tumors such as colorectal cancer, gastric cancer, and pancreatic cancer. LBL-061 is a novel EGFR/PD-L1 bispecific ADC, linked through the company's proprietary TOPiKineticsTM linker payload platform. It combines tumor-targeted killing and immune activation of ADC, synergistically enhancing anti-tumor effects, and is suitable for solid tumors such as head and neck cancer, non-small cell lung cancer, and nasopharyngeal cancer.